Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Onco360 Oncology Pharmacy

News headline image
Onco360® Has Been Selected as a National Specialty Pharmacy Provider for JYLAMVO® (methotrexate) Oral Solution
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a National Specialty Pharmacy Provider for IMKELDI® (imatinib) Oral Solution
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as the National Pharmacy Partner for UNLOXCYT™ (cosibelimab-ipdl)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Partnered with Rigel Pharmaceuticals to Add Three Therapies to Its Limited Distribution Portfolio
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as The National Specialty Pharmacy Partner for HYRNUO® (sevabertinib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Komzifti™ (ziftomenib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a Specialty Pharmacy Partner for INLURIYO™ (imlunestrant)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Wayrilz™ (rilzabrutinib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a Specialty Pharmacy Partner for HERNEXEOS® (zongertinib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a Specialty Pharmacy Partner for LYNOZYFIC™ (linvoseltamab-gcpt)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy for Augtyro™ (repotrectinib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for ROMVIMZA™ (vimseltinib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for AVMAPKI™FAKZYNJA™ CO-PACK
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for GOMEKLI™ (mirdametinib), Manufactured By SpringWorks Therapeutics
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Vyloy® (zolbetuximab-clzb)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Revuforj® (revumenib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Itovebi™ (inavolisib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as The National Specialty Pharmacy Partner for Tevimbra® (tislelizumab-jsgr)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
LAZCLUZE™ (lazertinib) Now Available from Onco360 for the First-line Treatment, in Combination with Rybrevant®, of Adult Patients with Metastatic Non-Small Cell Lung Cancer Whose Tumors Have EGFR Exon 19 Deletions or Exon 21 L858R Mutations
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for VORANIGO® (vorasidenib)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360® Has Been Selected as a National Specialty Pharmacy for crovalimab-akkz
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
CORRECTION -- Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Selected as a Limited Distribution Specialty Pharmacy Partner for Rytelo™ (imetelstat)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
OJEMDA™ (tovorafenib) Now Available from Onco360 for the Treatment of Patients Six Months of Age and Older with Relapsed or Refractory Pediatric Low-Grade Glioma (LGG) Harboring a BRAF Fusion or Rearrangement, or BRAF V600 Mutation
From Onco360 Oncology Pharmacy
Via GlobeNewswire
News headline image
Onco360 Has Been Selected as the Sole National Specialty Pharmacy Partner for Voydeya® (danicopan)
From Onco360 Oncology Pharmacy
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.